We developed an AIDS vaccine for Western and West-Central Africa founded on HIV-1 subtype CRF02 _ AG. Rhesus macaques were primed with Gag -Pol -Env-expressing plasmid DNA and boosted with a recombinant modified vaccinia virus Ankara (rMVA), expressing matched proteins. Two DNA vaccine constructs (IC1-90 and IC48) that differed by point mutations in gag and pol were compared. IC1-90 produces primarily immature (core comprises unprocessed Pr55Gag) HIV-like particles (VLPs) and IC48 produces mature VLP with processed Pr55Gag, immature VLP, and intracellular protein aggregates. Both vaccines raised significant cellular responses for Gag, Pol, and Env. Approximate twofold higher ELISPOT responses to Gag and Env epitopes were observed for IC48 animals than for IC1-90 animals at the peak post-MVA effector (P = 0.028) and late memory (P = 0.051) phases, respectively. Greater breadth for IC48-primed animals was observed than for IC1-90-primed animals at peak response (P = 0.03). Our results indicated that the vaccines elicited high frequency T cell responses and primed anti-Env antibody. They also suggest that expression of different forms of VLP has a significant effect on elicited cellular and humoral immunity. Published by Elsevier Inc.
Introduction
Many novel candidates and approaches have been developed in the pursuit to identify an effective human immunodeficiency virus (HIV) vaccine. The induction of strong cell-mediated immunity and broadly reactive antienvelope antibodies that can neutralize primary HIV-1 may be necessary in the making of an effective HIV-1 vaccine, and the ideal vaccine may need to induce both T and B cell responses. Plasmid DNA vaccination can elicit both humoral and cellular immune responses (Tang et al., 1992; Ulmer et al., 1993; Wolff et al., 1990 ) that protect nonhuman primates against challenges with nonpathogenic AIDS viruses (Boyer et al., 1997; Letvin et al., 1997) and afford modest protection against disease from pathogenic simian immunodeficiency virus (SIV) (Egan et al., 2000; Lu et al., 1996) .
Vaccines that have been designed to raise cellular immunity can in some cases control virulent viral challenges and prevent the development of AIDS in rhesus macaques (Amara et al., 2001; Barouch et al., 2000 Barouch et al., , 2001 Rose et al., 2001; Shiver et al., 2002) . Priming the immune response with plasmid DNA followed by a recombinant poxvirus booster such as the modified vaccinia virus Ankara (Amara et al., 2001; Robinson et al., 2000) or a VLP-protein boost plus IL-12/GM-CSF (O'Neill et al., 2003; O'Neill et al., 2002 ) are two of the many different approaches to raising cellular immunity. Including multiple HIV-1 gene regions on the same vector augments the DNA prime-MVA boost approach, as both gag and env responses are important to protection against virus challenge (Amara et al., 2002) . Lacking this potential advantage are HIV-1 DNA vaccines that encode only Gag or encode Gag, Env, and other viral proteins on separate DNA constructs (Barouch et al., 2000 (Barouch et al., , 2002 Kang et al., 1999) . Escape by HIV is possible when the immune response is driven by a single dominant epitope (Barouch et al., 2002 (Barouch et al., , 2003 Mortara et al., 1998) ; thus, a multi-epitope or multi-protein response appears advantageous.
It is well established that VLP assembly and release from cells depend on proper intracellular protease regulation to preserve the Gag polyprotein (Gottlinger et al., 1989; Karacostas et al., 1993; Peng et al., 1989) and may be observed upon transfection of Gag-only expression systems (Huang et al., 2001; Kang et al., 1999; Schneider et al., 1997) . Previous studies demonstrated that alteration of the 25th residue of protease, from Asp (D) to Asn (N), resulted in complete loss of protease activity (Gottlinger et al., 1989; Kohl et al., 1988; Loeb et al., 1989) . Furthermore, Jacobsen et al. (1995) demonstrated that mutagenesis of protease at positions 48 (G48V) and 90 (M90L) led to less efficient enzymatic activity and delayed processing of the gag and gag -pol polyproteins. Protease mutations at either amino acid positions 48 and 90 delay, but do not abolish, protease enzymatic activity, unlike the D25N mutation, and permit production of infectious virus when present within an otherwise wild-type provirus. A recent study suggested that the two protease mutations at positions 48 and 90 are not limiting, not only in terms of high-level production of HIV-1 proteins, but also with regard to assembly of VLPs (Ellenberger et al., 2004) .
One of the most promising HIV vaccines is the heterologous prime-boost approach. The prime may consist of a recombinant plasmid DNA or viral vector-expressing HIV proteins. The heterologous boost would be a recombinant viral vector (poxvirus or adenovirus) or second viral vector, optimizing the boost for the vaccine insert immunogen and not the vector itself. Using the same recombinant viral vector for the prime and boost may lead to a diminished immune response similar to preexisting immunity to the recombinant vector (Vogels et al., 2003) . Priming with a recombinant plasmid DNA and boosting with a recombinant MVA enhances the cellular responses to a common immunogen contained in both vectors (Amara et al., 2001; Hanke et al., 1998; Schneider et al., 1998 Schneider et al., , 2001 . At the peak effector phase of the immune response to the vaccine protocol, induced CD8 cells can reach very high frequencies of total CD8 cells (Allen et al., 2000; Amara et al., 2001; Horton et al., 2002) .
We undertook this study to test the immunogenicity of two HIV-1 recombinant subtype CRF02 _ AG DNA vaccines boosted with an identical MVA in rhesus macaques. Both DNAs expressed matched Gag -Pol -Env proteins and produced enveloped noninfectious VLPs. The DNAs differed on two accounts: product expression and safety mutations. For IC48, additional safety mutations were added and these include inactivating point mutations in packaging sequences in both nucleocapsid zinc fingers and three inactivating point mutations in RT which abrogate reverse transcription and RNase H and strand transfer activities as previously described (Ellenberger et al., 2004; Smith et al., 2004a Smith et al., , 2004b . By introducing distinct point mutations within Pol protease, the composition of the virus core was changed; the IC1-90 core comprised unprocessed Pr55Gag (immature VLP) and IC48 had processed Pr55Gag. Another outcome of the IC48 protease mutation was the production of multiple antigenic forms whereas IC1-90 had one form, immature VLP. Verification that the additional point mutations of gag and pol RT would not be detrimental to expression and could be potentially introduced if needed for reasons of safety was also evaluated. Both DNA/MVA vaccines raised significant and broadly reactive CD4 and CD8 T cell responses with high frequencies of IFN-g and IL-2-producing T cells specific for Gag and Env, as measured by ELISPOT and intracellular cytokine (ICC) staining assays. The multi-protein, heterologous DNA/MVA vaccine approach may induce protective immune recognition of HIV-1.
Results

Vaccine immunogens
To assess the assembly of VLPs, transfection culture supernatants were banded through a sucrose gradient and subsequent fractions were examined for the presence of Gag. Peak VLP fractions were analyzed by immunoblotting using rabbit polyclonal anti-p24 antibody (Fig. 1A) . Only two Gag polyproteins, p55 and p41, were detected for IC1-90. Three forms of Gag (p55, p41, and p24) were observed for IC48. The presence of Gag p24 indicates cleavage of the Gag polyprotein. As previously demonstrated, complete inhibition of HIV protease activity by saquinavir (HIV-1 protease inhibitor) or vaccine construct IC25 (genetic modification of protease activity) results in the Gag protein being primarily p55, indicating no cleavage of the Gag polyprotein (Ellenberger et al., 2004) . A summary of the vaccine constructs with corresponding protease mutations which result in the production of assorted products, including HIV protein aggregates and VLPs containing complete to partial cleavage of Gag, is shown in Fig. 1B .
To confirm partial inhibition of protease activity permitted VLP assembly and possible particle maturation, cells transfected with protease-mutant vaccine constructs were examined by electron microscopy (Fig. 1C) . For IC1 -90, immature VLPs were seen (Fig. 1C) . These particles were uniformly sized, abundant in number, and similar in appearance (electron-dense shells and lucent centers) to those formed by expression in the presence of saquinavir and IC25 (Ellenberger et al., 2004) . Budding structures and numerous VLPs were also observed for IC48 (Fig. 1C) . However, two distinctive particle morphologies were observed: VLPs with a spherical protein shell (immature) and other particles with electron dense centers (mature). Furthermore, the VLP with electron-dense centers had a lean spherical protein shell, suggesting cleavage of Gag p55 and condensing of the viral core, comparable to mature HIV particles. IC48-transfected cells were also observed to contain intracellular aggregates of HIV proteins (Fig. 1C) .
Total Gag expression was detected by antigen-capture ELISA following 293T cell transfection; IC1-90 expression appeared sharply diminished as compared with IC48, 131, and 878 ng/ml, respectively. In the supernatant and cell lysate, Gag protein levels were 77 and 54 ng/ml (IC1-90) and 624 and 254 ng/ml (IC48), respectively. However, as previously reported (Schneider et al., 1997) , the detection efficiency of Gag p55 was substantially less than that of Gag p24. Therefore, quantification of total Gag protein of transfection supernatants by Western blot analysis as measured by phosphorimager demonstrated that IC1 -90 expressed Gag protein to a level similar to IC48, 1771, and 1570 relative units. For IC1 -90, the Gag protein was primarily p55 (61% of the immunoreactive protein). Production of Env protein was also detected by ELISA, and IC1 -90 and IC48 Env levels were similar, 696 and 665 ng/ml, respectively. A greater percentage of total Env protein was detected in the supernatant for both constructs (data not shown).
Preclinical safety testing
Three DNA primes at 0, 8, and 26 weeks and a single rMVA booster at 41 weeks were administered in 1 ml by IM needle injections. DNA priming was 0.6 mg of either IC1 -90 or IC48 per injection and MVA booster was at 1 Â 10 8 pfu. All 16 macaques received identical aliquots only differing by the priming agent, IC1-90, or IC48. Physical examinations, daily observations, measuring for weight, hematology, and clinical chemistry were completed (data not shown). No local redness or indurations at the injection site were observed.
ELISPOT analysis
Vaccine-elicited T cells expanded rapidly after the MVA booster (Fig. 2) . Prior to the MVA booster, HIV-1-specific ELISPOT responses were at, or below, our background for detection following each of the DNA primes. Temporal ELISPOT analyses revealed that the highest ELISPOT response was 1 week after the MVA booster (Peak). Frequencies up to 5300 spots per one million peripheral blood mononuclear cells (PBMC) were found at the peak response. This peak of specific cells underwent a threefold contraction into the DNA/MVA memory pool (8 weeks post-MVA). T cell responses contracted an additional threefold at 26 weeks post-peak (late memory). Regardless of the immune phase (peak, memory, or late-memory) total ELISPOTS were greater for IC48-primed animals than IC1-90-primed animals; the T cell responses for IC48 animals were 2.2-fold greater (arithmetic mean) than IC1-90 animals. A random effects model using a linear regression of the aggregate ELISPOT values on group and time demonstrates that IC48 is higher than IC1-90, group effect has P value = 0.002 in the model. Furthermore, at peak response (P = 0.028) and late memory (P = 0.051), significantly higher responses by IC-48-primed animals were observed.
At the peak response, both of tested plasmid DNAs successfully primed the MVA booster for an anti-viral IFN-g ELISPOT response to Gag, Pol, and Env sequences. The analyses revealed greater than twofold differences between the IC48 and IC1-90 primes (Fig. 3 ). The twofold difference was significant and observed in all tested gene regions of the virus, including Gag (P = 0.015), Pol (P = 0.047), and Env (P = 0.0003). For Pol and Env, the total ELISPOT mean responses were less than the response observed in Gag, but the twofold difference is evident. The limited Tat response was expected as Tat was not a common immunogen in the recombinant plasmid and rMVA.
A broad ELISPOT response for both Gag and Env was present 1 week after the MVA booster (Fig. 4) . Greater breadth of response to peptide pools for IC48-primed animals was observed than IC1-90-primed animals (P = 0.03). At the peak response, each of the 5 pools of Gag peptides and 7 pools of Env peptides was recognized by at least 3 of the immunized animals. On average per animal, 2.8 Gag and 2.9 Env peptide pools stimulated a cellular response as measured by ELISPOT. Much lower frequencies of responses were elicited for PR, RT, and Tat, but these pools were recognized by at least one or more of the animals. Four of the 16 animals recognized the one pool of PR peptides, 7 recognized one of the 5 pools of RT peptides, and one animal's cells were stimulated by the pool of Tat peptides.
Consistent with the height of the ELISPOT response, T cells from IC48-primed animals recognized more peptide pools than observed with IC1-90-primed animals (Table 1 ). In the IC1 -90 group, 6 of 8 animals responded to at least one Gag pool with an overall average of 2.5 of 5 pools being recognized (Table 1, Fig. 4 ). For the IC48 group, 7 of 8 animals responded to at least two Gag pools with an overall average of 3.1 pools being recognized. The Env response was similar in the IC48 group where 7 of 8 animals responded to at least two pools. In the IC1 -90 group, only 6 of 8 animals responded to Env, recognizing at least one Env pool. In the memory phase of the immune response, less peptide pools stimulated T cell responses in all the vaccinated animals, but IC48 animals responded to more peptide pools than the IC1 -90 group (5.3 vs. 3 pools), respectively.
A broad response for both Gag and Env was retained 8 weeks post-MVA booster (Fig. 5 ). In the memory phase, IC48-primed animals responded to more epitopes (P = 0.004) than IC1 -90-primed animals. Frequencies up to 2125 spots per million PBMC were found at the memory phase. Fifteen of the 16 animals recognized at least one pool of peptides. Monkeys AC36 and M509, initially nonresponders at 1-week post-MVA, were shown to recognize at least one Gag pool at 8 weeks post-MVA. Animal O2L remained nonresponsive to the peptide pools. At the memory response, each of the 5 pools of Gag peptides and 5 of 7 Env peptide pools were recognized by at least one of the immunized animals.
Intracellular cytokine analysis
To determine the frequencies of responding CD4 and CD8 T cells, intracellular cytokine assays were performed (Fig. 6 ). Peptide induction of IFN-g and IL-2 expression in CD4 and CD8 lymphocytes was measured, and both tested plasmid DNAs successfully primed the MVA booster. One week following the MVA booster, peak responses were observed as seen by ELISPOT analyses. Regardless of the gene region, the response by IC48-primed animals was significantly greater than IC1-90-primed animals: Env (P = 0.006) and Gag (P = 0.026). CD8 cells specific for Gag epitopes expanded to frequencies as high as 2.6% of total CD8 T cells in one animal. Intracellular cytokine staining for IFN-g expression and IL-2 revealed an approximate fourfold difference to Gag peptides between the DNA plasmids; IC48 primed more CD8 cells than IC1-90. The geometric mean of percent-specific CD8 cells was 0.54 vs. 0.14 for the IC48 group and IC1-90 group, respectively. A twofold difference was detected in the Env region (0.28 vs. 0.14). The same ratios were observed regardless of the expressed cytokine. In several animals, CD4 cells specific for Gag epitopes expanded to frequencies as high as 0.5% of the total CD4 T cells (Fig. 6) . Statistical analyses revealed that a significantly greater number of CD4 cells specific for Env epitopes were observed for the IC48-primed animals than IC1 -90 animals (P = 0.006). However, staining for IFN-g expression and IL-2 revealed a fourfold difference (0.39 vs. 0.11 geometric means) to Env peptides and twofold difference (0.31 vs. 0.15) for Gag peptides between the DNA plasmids. Overall, CD4 cell responses were significantly greater than CD8 cell responses (P < 0.0001).
Based on Fig. 6 data, geometric means were determined to compare specific cells (CD4 and CD8), cytokines expressed (IFN-gand IL-2), and HIV gene regions. Peptide induction of IL-2 expression in CD4 lymphocytes was twofold greater than the percent-specific CD8 lymphocytes (0.113 vs. 0.056 geometric mean). However, CD8 and CD4 cells were similar for IFN-g expression (0.089 vs. 0.078 geometric mean). In the Gag region, IFN-g expression was significantly greater than IL-2 expression (P = 0.013), but CD4-IL2, CD8-IL2, and CD8-IFN-g expressions were significantly greater than CD4-IFN (P = 0.032).
The average number of peptide pools recorded as positive by intracellular cytokine staining to include both IFN-g and IL-2 expression were found to be relatively comparable between DNA priming groups regardless of the gene region (Table 1) . At the peak immune response, IC1-90 animals would require a 31% and 11% increase in peptide pool responses to equal the response of IC48 animals for CD8 and CD4 cells, respectively. However, threefold more peptide pools induced IFN-g and IL-2 expression in CD4 cells than CD8 cells (6.25 vs. 2.2 pools). This same threefold ratio was observed for both IC1-90-and IC48-primed animals.
Antibody responses
The antibody response was strongly boosted by the MVA. By Western blot analysis, negligible binding antibody was elicited by DNA priming, but 11 of 16 animals (6 IC1-90 and 5 IC48 monkeys) showed Env reactivity against an HIV-1 subtype AG virus lysate 3 weeks following the MVA. All 11 reactive animals produced antibody which detected Env gp120 and only one animal responded to Gag p24. There was no difference between the two groups of primed animals.
Anti-Env titers were determined for the vaccinated animals by solid-phase Env ELISA. At 3 weeks post-MVA, the average reciprocal titers were 1075(T1569) and 2119(T1898) for the IC1 -90-and IC48-primed animals, respectively. The titers fell to 953(T979) and 850(T563), respectively, at 8 weeks after the booster. There was no substantial difference observed between the two groups of animals.
Tests for neutralizing antibody revealed very low levels of activity for the primary isolate used for the vaccine; only one animal scored positive. The primary isolate, a recombinant HIV-1 subtype AG, was relatively resistant to neutralization by many other sera and neutralizing monoclonal antibodies (data not shown). The neutralizing activity of the plasma also did not score for HIV-1-MN (subtype B), a laboratory-adapted isolate against HIV-1.
Discussion
These studies reaffirm the utility of DNA-and MVAvectored vaccines for producing cellular immunity and suggest that successive immunization with DNA and MVA vaccines expressing several common protein immunogens can be an effective way of inducing broadly reactive CD4+ and CD8+ T cells. Furthermore, a novel and provocative finding of this preclinical study is that in a DNA vector with an HIV-1 vaccine insert capable of producing multiple antigenic forms, including immature VLPs, mature VLPs, and protein aggregates may significantly prime more antiGag and anti-Env T cells, lasting beyond the peak effector phase. We suggest that the production of multiple antigenic forms, including VLPs with matured cores, may be an improvement over one form such as immature VLPs with unprocessed Pr55Gag, and potentially more robust than single gene DNA constructs or single gene DNA plus polyepitope constructs (Hanke et al., 2002; Mwau et al., 2004) . Furthermore, the introduction of additional safety measures that ablates integration, reverse transcription, and RNA packaging is not detrimental to immunogenicity.
Given the lack of understanding of correlates of immune protection and the basic biology of HIV disease, a vaccine that generates a broadly reactive response and induces a sizeable pool of long-lasting, protective memory T cells of both CD4 and CD8+ T cells may be practical and efficacious. Many DNA vaccines have been developed and tested in either preclinical or human trails, but not all DNA vaccines are alike. DNA vaccines may encode only Gag or encode Gag, Env, and other viral proteins on separate DNA constructs or Gag plus a string of multiple CTL epitopes (Barouch et al., 2000 (Barouch et al., , 2002 Kang et al., 1999; Mwau et al., 2004) . Despite the encouraging demonstration in humans in Nairobi of a safe DNA/MVA vaccine (Mwau et al., 2004) , there was a lack of a strong showing of immunogenicity, but this DNA vaccine was built on only 365 AA of Gag and a string of 25 overlapping CTL epitopes. Our DNA vaccine is significantly (fourfold) larger (2386 amino acid residues) and encodes HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu. Results from this preclinical nonhuman primate immunogenicity trail and others (Amara et al., 2001; Smith et al., 2004a Smith et al., , 2004b have demonstrated significant and broadly reactive CD4 and CD8 cellular responses using a multi-gene approach. Numerous epitopes throughout the HIV genome participated in the cellular immune response and clearly broad cellular responses are very important for limiting viral escape (Barouch et al., 2002 (Barouch et al., , 2003 . Incorporating multiple HIV-1 gene regions on the same DNA construct should augment the prime boost combination and reduce the likelihood of limited immunogenicity and viral escape to single epitope.
As recently demonstrated in healthy low-risk volunteers in Oxford and Nairobi, the overall DNA and MVA approach, including the candidate DNA and MVA vaccines by themselves and as a prime boost combination, has been confirmed to be safe (Mwau et al., 2004) . The additional safety measures introduced into our vaccine construct proved not to be disadvantageous and may be included in the DNA prime without the need to strike a balance between safety and effectiveness of the vaccine as both the height and breadth of the elicited cellular response by the IC48-primed animals were robust. Altering the original HIV sequence by creating specific point mutations within Gag and Pol was not detrimental to in vivo expression (data not shown). The identical mutations in an HIV-1 subtype B construct reduced viral RNA packaging within the VLPs and completely eliminated viral RNA reverse transcriptase activity (Smith et al., 2004b) .
The production of noninfectious enveloped VLPs and multiple antigenic forms may potentially improve the effectiveness of a DNA/MVA vaccine and may provide the best level of protection by controlling HIV-1 replication and perhaps infection. We sought to optimize expression of the DNA vaccine, not only in terms of high-level production of HIV-1 proteins, but also with regard to assembly of VLPs constructed from multiple HIV proteins. Our in vitro data suggested that VLPs with matured cores may be an Fig. 6 . Responding CD8 and CD4 cells determined by IFN-g and IL2 intracellular cytokine staining. (A) Percent-specific CD8 cells responding to Gag and Env for individual animals at peak (1 week after the MVA booster). The bold bar indicates the arithmetic mean height for the response in each group. Designations above the panels specify the measured cytokine (IFN-g or IL2) and designations below the panels specify the DNA prime group. Symbols indicate the individual animals. (B) Percent-specific CD4 cells responding to Gag and Env for individual animals at peak (1 week after the MVA booster). Designations above and below the panels are the same as in panel A. improvement over the immature VLP (Ellenberger et al., 2004) and our findings in this immunogenicity trial support these in vitro findings as the height of the immune response was greater for mature VLPs. Shifting the qualitative production of HIV products from an aggregate-forming DNA to a VLP-forming DNA was not remarkable as these constructs were similar in their ability to prime an MVA boost (Smith et al., 2004a) . However, including fusioncompetent mature VLPs by candidate DNA or other livevectored vaccine constructs may provide immunological advantages for induction of protective cellular and humoral responses against HIV-1. There may be an even greater difference between the two DNA vaccines since the efficiency of the priming by the two different DNA constructs could be minimized by virtue of the highly effective MVA booster.
The development and characterization of HIV-1 DNA vaccines that generate a balance of these different antigenic forms constructed from multiple HIV proteins may provide distinct immunologic advantages and further advance vaccine development. The level of virus-specific CD8+ T cells induced by vaccination of macaques may indicate an antiviral role for vaccine-elicited CD8+ T cell responses in the animal model of vaccine efficacy. The production of mature virus-like particles, which may behave similarly to attenuated live-virus vaccines but without risk of integration or causing AIDS, is clearly an obtainable goal for multigene/multi-protein HIV-1 DNA vaccine approaches. It remains to be determined from preclinical trials whether either one of these DNA vaccines, when coupled with an MVA booster, will provide protection from HIV-1 infection or disease progression.
Materials and methods
DNA immunogens
DNA constructs were made in the pGA1 expression vector (GenBank accession no. AF425297) that includes intron A in the promoter cassette and uses the CMV immediate -early promoter and the bovine growth hormone polyadenylation sequence to express RNAs (Chapman et al., 1991; Ross et al., 2000) . An incident recombinant HIV-1 subtype AG (CRF02 _ AG) strain IC0928 was reverse transcribed (GenBank accession no. AY227361 and AY227362), and fragments produced by DNA PCR were cloned into the pGA1 expression vector (Ellenberger et al., 2002 (Ellenberger et al., , 2004 . Construction and description of pGA1/IC48 (IC48) have been previously described (Ellenberger et al., 2004) . pGA1/IC1 -90 (IC1 -90) differs from IC48 by point mutations in gag and pol. Briefly, IC1-90 lacks the introduced point mutations in gag NC zinc fingers and pol RT as previously described for IC48 (Ellenberger et al., 2004; Smith et al., 2004a Smith et al., , 2004b . IC1 -90 and IC48 also differ in their protease sequence where there are two substitutions in IC1 -90, an Arg-to-Gly substitution at position 70 and Met-to-Leu substitution at position 90. IC48 has a Gly-to-Val substitution at position 48 as previously described. The protease mutations were made using a site-directed mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer's protocol. All mutations were confirmed by sequencing.
Recombinant MVA immunogen
A recombinant MVA expressing gag, pol, and env regions derived from IC0928 will be described elsewhere (Wyatt and Moss, unpublished data) . Briefly, it was constructed with gag -pol inserted into deletion III and a truncated env into del II as described previously for MVA/ SHIV89.6 with the modification that a transient GFP marker for obtaining recombinant virus was used, similar to the transient GUS described by Wyatt et al. (2004) .
Cell line and transient transfections
Human 293T cells, a human kidney-derived cell line, were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum. 293T cells were added at 10 6 cells/well of Costar 6-well plates in 2 ml of DMEM growth medium and incubated for 24 h at 37 -C in a 5% CO 2 humidified atmosphere. After 24 h, LipofectAmine2000 reagent (Invitrogen, Carlsbad, CA) and plasmid DNA were mixed according to the manufacturer's protocol and added to each well. Supernatants were harvested 24 or 48 h following the addition of transfection reagents.
Purification of particles
Following 24 h of transient transfection of 293T cells, culture supernatants were recovered, clarified by centrifugation at 200 Â g for 5 min, and 1 ml was layered on top of 10-50% sucrose gradients. Gradients of 10 ml consisting of 2 ml each of 50%, 40%, 30%, 20%, and 10% sucrose solutions were added to ultraclear centrifuge tubes from bottom to top. Gradients were centrifuged at 40,000 rpm for 16 h in SW41Ti rotor. Fractions of 1 ml were recovered, top to bottom. Fraction aliquots were analyzed by HIV-1 p24-antigen-capture assay.
Electron microscopy
Transfected 293T cells were fixed in the multi-well plate using 1 ml of 2.5% glutaldehyde in 0.1 M cacodylate buffer for 2 h at 4 -C. After three washes with the same buffer, 1.0% osmium tetroxide in 0.1 M cacodylate buffer was added, incubated for 1 h, dehydrated through an ethanol series, and embedded with Eponate 12 resin. Following polymerization of the resin, the cells were sectioned en face, stained with 4% uranyl acetate in water and lead citrate, and observed on a Hitachi H-7500 transmission electron microscope.
Antigen-capture assay
Assay was performed using an HIV-1 antigen-capture EIA kit (Coulter, Hialeah, FL) according to the manufacturer's instructions.
Env ELISA
Pooled human immunoglobulin anti-HIV (catalog no. 3957) was obtained from the National Institute of Allergy and Infectious Diseases AIDS Research and Reference Reagent Program (Rockville, MD). Env ELISA was done as previously described (Ellenberger et al., 2004) .
Macaques and immunogenicity trial
Sixteen young adult male outbred rhesus macaques (Macaca mulatta) of Indian origin were randomized by weight into two vaccine groups of 8. The IC1-90 group received 0.6 mg of IC1 -90 DNA and the IC48 group received 0.6 mg of IC48 DNA intramuscularly (IM) at weeks 0, 8, and 26. DNA immunizations were delivered in phosphate-buffered saline with a needle and syringe. A total of 3 injections were delivered to the upper lateral right thigh in a volume of 1 ml/injection. Fifteen weeks following the 3rd DNA immunization (week 41), all animals received 1 Â 10 8 pfu of a modified vaccinia Ankara virus (MVA/HIV) booster IM using a needle and syringe in the upper lateral right thigh. The MVA immunization was delivered in phosphate-buffered saline in a volume of 1 ml. Injection sites were monitored for local inflammatory reactions.
Humoral responses
Western blot analysis of whole virus lysate and sucrosepurified VLP was performed as previously described (Sambrook et al., 1989) . Whole virus lysate (IC0928) was run on 4 -15% gradient SDS gel and transferred to nitrocellulose. Plasma samples were diluted 1:100 in blocking buffer. The secondary antibody was anti-human IgG (Fab)-phosphatase and detection was completed by using the BCIP/NBT phosphatase substrate system (KPL, Gaithersburg, MD) according to manufacturer's instructions. Analysis of sucrose-purified VLP was completed using rabbit polyclonal anti-p24 (catalog no. 4250) which was obtained from the National Institute of Allergy and Infectious Diseases AIDS Research and Reference Reagent Program. HIV-1 Gag protein bands were visualized using the ECL Western blotting detection reagent (Amersham Pharmacia Biotech, Piscataway, NJ) as described by the manufacturer. Expression levels were determined using a phosphoimager.
To measure the levels of Env IgG in sera of immunized monkeys, 96-well U-bottom plates were coated with sheep antibody to the C-terminus of gp120 followed by purified CRF02 -AG gp140 as previously described . The time of incubation of serum dilutions was increased from 2 h to overnight for enhanced sensitivity of the ELISA.
Neutralization was measured as a function of reductions in luciferase reporter gene expression after a single round of infection in TZM-bl cells as described (Montefiori, in press ). TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program, as contributed by John Kappes and Xiaoyun Wu. Briefly, 200 TCID50 of virus was incubated with serial threefold dilutions of serum sample in triplicate in a total volume of 150 Al for 1 h at 37 -C in 96-well flat-bottom culture plates. Freshly trypsinized cells (10,000 cells in 100 Al of growth medium containing 75 Ag/ml DEAE dextran) were added to each well. Indinavir was added at a final concentration of 1 AM to prevent replication in the case of HIV-1 MN. One set of control wells received cells + virus (virus control) and another set received cells only (background control). After a 48-h incubation, 100 Al of cells was transferred to a 96-well black solid plates (Costar) for measurements of luminescence using Bright Glo substrate solution as described by the supplier (Promega). An assay stock of virus pseudotyped with gp160 from the CRF02 -AG vaccine strain was prepared by transfection in 293T cells and titrated in TZMbl cells. The assay stock of HIV-1 MN was prepared in H9 cells.
Peptide pools
HIV-1 recombinant subtype CRF02 -AG peptides were 15mers overlapping by 11 derived from the vaccine strain. Peptides were assembled into pools containing approximately 25 peptides. Peptides were dissolved in DMSO at 50 -100 mg/ml and stock solutions maintained at À70 -C. Peptide working solutions were kept at À20 -C for 1 week.
T cell assays
ELISPOT assays were done as previously described (Amara et al., 2001 (Amara et al., , 2002 , except that 2 Ag/ml of antibody to human CD28 and CD49d (Becton Dickinson, San Jose, CA) was included in incubations (Waldrop et al., 1998) . Purified PBMC were plated in duplicate in 96-well plates at 2 Â 10 5 cells/well with peptide pools used at a final concentration of 10 Ag/ml for each peptide. Four wells received only media. Plates were incubated at 37 -C, 5% CO2 for 36 h, and spots counted using an ELISPOT reader. Background was set at 2Â the average of the negative control wells plus 10. This background value was subtracted from the raw counts of the peptide wells before conversion to 1 million PBMC. Only ELISPOT counts of twice the background (>100) were considered significant. Intracellular cytokine (ICC) staining assays for IFN-g and IL-2 have been described previously (Amara et al., 2001 (Amara et al., , 2002 . For those assays, one million PBMC were resuspended in 100 Al of RPMI in a 5-ml polypropylene tube and stimulated with 100 Ag/ml of the peptide pool in the presence of anti-CD28 and anti-CD49d antibody at a final concentration of 1 Ag/ml. The cells were incubated at 37 -C, in a tissue culture incubator at an angle of 5-in 100 Al. At 2 h, 900 Al of medium with 10 Ag of Brefeldin A was added and the incubation continued for an additional 4 h. Cells were then stained for CD3, CD8, CD69, IFN-g, and IL-2 fixed with 1% formaldehyde in PBS, and acquired within 24 h on a FACScaliber (Becton Dickinson, San Jose, CA). Approximately 150,000 lymphocytes were acquired for each sample. Data were analyzed using FloJo software (Tree Star, Inc., San Carlos, CA).
Statistical analysis
The Wilcoxon test for independent samples and signedrank test were used for comparison of immunogenicity tests from groups primed with the two DNA vaccines. A mixedeffects model using a linear regression of the aggregate ELISPOT values on group (IC-48 or IC1 -90) and time with monkeys as the random effect was used. Also, a mixedeffects linear regression model was used for testing responses of CD4 versus CD8 T cells, T cell responses against Gag versus Env, and IFN-g and IL-2 expression.
